← All trials
NCT06717685
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 28, 2024
- Primary completion
- Jan 27, 2025
- Completion date
- Feb 3, 2025
- First posted
- Dec 5, 2024
- Last posted
- Dec 5, 2024
- Enrollment
- 210
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rashid Latif Medical CollegeLead sponsor
- Rashid Latif Medical CollegeSponsor investigator
- University of the PunjabCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.